摘要
目的：检测肾透明细胞癌患者血清中 miR-193a-3p 的表达水平，探讨其作为肾透明细胞癌分子诊断指标的可能性。方法收集南京军区南京总医院2010-2014年期间107例住院肾透明细胞癌患者（TNM 分期Ⅰ期76例、Ⅱ期16例、Ⅲ期2例、Ⅳ期8例和未知5例）未经治疗前血清样本，实时荧光定量 PCR（qRT-PCR）方法检测 miR-193a-3p 含量，并以107例年龄、性别匹配的非癌健康人作对照。ROC 曲线分析血清 miR-193a-3p 水平对肾透明细胞癌的早期诊断价值。结果qRT-PCR 检测证实，miR-193a-3p 在总体患者血清中的含量显著高于对照组（3.294±1.526 vs 1.944±0.600，P＝0.000）。TNM Ⅰ期（3.411±1.676 vs 1.944±0.600，P ＝0.000）、Ⅱ期（2.926±0.927 vs 1.944±0.600，P ＝0.001）和Ⅳ期患者（2.926±0.894 vs 1.944±0.600，P ＝0.000）血清中 miR-193a-3p 的表达水平均明显高于对照组。用于诊断肾透明细胞癌早期（Ⅰ期）的血清 miR-193a-3p ROC 曲线下面积（AUCROC）为0.820（95％ CI，0.756-0.883），敏感度为80.3％，特异度为93.5％。结论miR-193a-3p 在肾透明细胞癌患者血清中的水平显著升高，并有较高的早期诊断准确性，有望作为该病早期诊断的血清学指标。
Objective To determine the levels of miR-193a-3p in serum from patients with renal clear cell carcinoma,and eval-uate the potential of miR-193a-3p asa molecular biomarker of renal clear cell carcinoma.Methods Serum samples were taken from 107 untreated hospitalized patients with renal clear cell carcinoma （TNM Ⅰ grade 76 cases,Ⅱ grade 16 cases,Ⅲ grade 2 cases,Ⅳ grade 8 cases and unknown 5 cases）in Nanjing General Hospital from 2010 to 2014 year and 107 age-and gender-matched healthy individuals to determine the level of miR-193a-3p by quantitative reverse-transcription PCR （qRT-PCR）. The early diagnostic value of miR-193a-3p for renal clear cell carcinoma was assessed by ROC curve.Results qRT-PCR confirmed that serum miR-193a-3p expression levels was significantly elevated in cancer than in normal controls （3.294± 1.526 vs 1.944±0.600,P =0.000）.TNM Ⅰ grade （3.411±1.676 vs 1.944±0.600,P =0.000）,Ⅱ grade （2.926±0.927 vs 1.944±0.600,P =0.001）,Ⅳ grade（2.926±0.894 vs 1.944±0.600,P =0.000）is significantly higher than that in con-trol group.The area under the ROC curve （AUC）of miR-193a-3p was 0.820 （95% CI,0.756 - 0.883）,demonstratinga high sensitivity （80.3%）and specificity （93.5%）for the early diagnosis of renal clear cell carcinoma.Conclusion MiR-193a-3p content was significantly elevated in serum from renal clear cell carcinoma and has a high accuracy in diagnosing ear-ly cancer,which holds potential as molecular biomarker for renal clear cell carcinoma.
出处
《现代检验医学杂志》
CAS
2015年第3期43-45,49,共4页
Journal of Modern Laboratory Medicine
基金
国家自然科学基金资助项目（81171661
81472021）
南京军区医学科技创新重点课题（12228）.南京军区南京总医院院管课题（2012058）.
